Mouse Thrombomodulin/BDCA-3 ELISA Kit

Thrombomodulin, also known as Fetomodulin, BDCA-3 and CD141, is a transmembrane protein encoded by the THBD gene in humans. Thrombomodulin is composed of an N-terminal C-type lectin domain, six contiguous epidermal growth factor (EGF)-like domains, a highly glycosylated serine/threonine-rich domain, a transmembrane segment, and a short C-terminal cytoplasmic tail. The full-length mouse Thrombomodulin is a 577 amino acid (aa) precursor protein containing a signal peptide and the mature polypeptide. Mature mouse Thrombomodulin is composed of a 501 aa extracellular domain (ECD) with a N-terminal C-type lectin domain and six EGF-like domains, a 24 aa transmembrane segment, and a 36 aa cytoplasmic domain. The ECD of mouse Thrombomodulin shares 66% and 85% aa sequence identity with human and rat counterparts, respectively. Thrombomodulin is expressed primarily by vascular endothelial cells. Thrombomodulin plays an important role in the anti-coagulation and fibrinolysis system. When the coagulation cascade is activated, prothrombin is converted to thrombin by coagulation factors Va and VIIIa, ultimately leading to fibrin clot formation. Thrombin binds to thrombomodulin and then activates protein C to degrade coagulation factors Va and VIIIa, thereby reducing the amount of thrombin generated and inhibiting coagulation. Thrombomodulin-thrombin complex also activates thrombin-activatable fibrinolysis inhibitor (TAFI), creating a carboxypeptidase that inhibits fibrinolysis. It has been shown that patients suffering from cardiovascular diseases, such as acute coronary syndrome, pulmonary thromboembolism, and severe hemorrhage, have increased circulating thrombomodulin concentrations.

62.5--4000pg/mL

100 uL final volume, dilution factor varies on samples